Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: A review

British Journal of Rheumatology

Volumn 36, Issue 2, 1997, Pages 158-163

  Rose, L M ^a   Latchman, D S ^a   Isenberg, D A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Apoptosis; bcl 2; Fas; Lymphocytes; Systemic lupus erythematosus

Indexed keywords

FAS ANTIGEN; PROTEIN BCL 2;

APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 0030791252     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.2.158     Document Type: Review

References (49)

1. Wangel AG. Serological tests in the assessment of disease activity in systemic lupus erythematosus. Scand J Rheumatol 1986;15:353-5.
2. Izui S, McConahey PJ, Dixon IJ. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol 1978;121:2213-9.
3. + cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25.
4. Ishida H, Kumagai S, Umehara H et al. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 1987;139:1070-4.
5. Sakane T, Steinberg D, Green I. Studies of immune functions of patients with systemic lupus erythematosus. Arthritis Rheum 1978;21:657-64.
6. Tsokas GC, Magrath IT, Barlow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983;131:1797-801.
7. Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JT. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989;337:181-4.
8. Schmid D, Tite J, Ruddle N. DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting higher T-cell clones, and cell-free lymphotoxin-containing supernatant. Proc Natl Acad Sci USA 1986;83:1881-5.
9. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptosis and necrotic forms of cell lysis. J Immunol 1988;141:2629-34.
10. Liu Y-J, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan ICM. Mechanism of antigen-driven selection in germinal centres. Nature 1989;342:929-31.
11. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
12. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
13. McDonnell JJ, Deane N, Platt FM et al. Bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;58:79-88.
14. Gmelig-Meyling F, Dawisha S, Steinberg AD. Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J Exp Med 1992;175:297-300.
15. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
16. Goel N, Ulrich DT, St Clair EW, Fleming JA, Lynch DH, Seldin MF. Lack of correlation between serum soluble fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995;38:1738-43.
17. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-7.
18. Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
19. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
20. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-42.
21. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987;80:1512-5.
22. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and co-operates with c-myc to immortalise pre-B cells. Nature 1988;335:440-2.
23. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
24. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225-32.
25. Reed JC, Miyashita T, Cuddy M, Cho D. Regulation of p26-Bcl-2 protein levels in human peripheral blood lymphocytes. Lab Invest 1992;67:443-9.
26. Katsuma M, Siegel RM, Louie DC et al. Differential effects of bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1992;89:11376-80.
27. Strasser A, Whittingham S, Vaux DL et al. Enforced bcl-2 expression in B lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991;88:8661-5.
28. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune disease and probes for cell biology. Adv Immunol 1989;44:93-151.
29. Basten A, Brink R, Peake P et al. Self-tolerance in the B-cell repertoire. Immunol Rev 1991;122:5-19.
30. Graninger WB. Transcriptional overexpression of the proto-oncogene bcl-2 in patients with systemic lupus erythematosus. Wien Klin Wochenschr 1992;104:205-7.
31. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
32. Smolen JS. Clinical and serological features: incidence and diagnostic approach In: Smolen JS, Zielensky CC, eds. Systemic Lupus Erythematosus, Clinical and Experimental Aspects. Berlin: Springer-Verlag pp. 170-96.
33. Aringer M, Wintersberger W, Steiner CW et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus crythematosus. Arthritis Rheum 1994;37:1423-30.
34. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73:109-14.
35. Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984;11:783-7.
36. Gatenby P, Irvine M. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 1994;7:623-31.
37. Rose LM, Isenberg DA, Latchman DS. Bcl-2 expression is unaltered in unfractionated peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Br J Rheumatol 1995;34:316-20.
38. Hay EM, Bacon PA, Gordon C. et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
39. + T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12.
40. Morimoto C, Steinberg AD, Letvin NL et al. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest 1987;79:762-8.
41. Klinman DM, Steinberg AD. Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med 1987;165:1755-60.
42. Wesselborg S, Jassen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993;150:4338-45.
43. Akbar AN, Borthwick N, Salmon M et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med 1993;178:427-38.
44. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1993;152:3685-92.
45. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
46. Boise LH, González-Garcia M, Postema CE et al. Bcl-x, bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
47. Boyd JM, Gallo GJ, Elangovan B et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995;11:1921-8.
48. Kiefer MC, Brauer MJ, Powers VC et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995;374:735-9.
49. Dhein J, Walezak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.